Tauriga Sciences Inc. Announces the Launch of Its taurigastore.com eCommerce Website
Thursday January 8, 2015 (Los Angeles, CA) — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, today launched its http://www.taurigastore.com eCommerce website. This launch allows consumers to shop online with the Company for its non-cannabis containing line of natural wellness dietary supplements. These natural supplements include IndiCalm, natural calming formula without inducing cognitive impairment; ClearNaze, a natural decongestant without stimulant or drowsiness effects; Satietiva, an amino acid-based appetite suppressant (preorder until February 2); and MendΩCan, a highly pure, potent and palatable Omega 3 supplement.
Tauriga’s Chairman & CEO Dr. Stella Sung stated, “We’re thrilled to launch our http://www.taurigastore.com eCommerce web site. It is a major milestone for our Company because it will enable us to start building our revenue stream with products we proudly believe will be a welcome solution for enhancing healing and lifestyle. Entering the online channel provides us with an additional opportunity for growth as well as an important opportunity to develop a closer relationship with our consumers by better understanding their product preferences and by having another avenue for communication. We believe these valuable insights will help us improve our consumers’ experiences with all of our products and will be useful input for our new product development strategy.”
In addition to Tauriga’s non-cannabis containing line of natural wellness dietary supplements, Tauriga recently launched its proprietary topical medicinal cannabis cream branded as TopiCanna. Many who have used topical cannabis creams have reported decreased musculoskeletal pain. TopiCanna is designed to provide potential natural wellness and healing properties without narcotic effects. TopiCanna’s key ingredient is cannabidiol (CBD) oil from non-GMO industrial hemp that is grown without pesticides, herbicides, or chemical fertilizers. The oil has been lab tested for quality and is natural, safe and legal in the United States. In addition to the CBD oil from non-GMO industrial hemp, the lotion contains ingredients for soothing dry skin, including shea butter and apricot kernel oil. TopiCanna is not offered through the http://www.taurigastore.comeCommerce web site, but interested parties may inquire about TopiCanna at email@example.com.
Tauriga’s Chief Medical Officer Lawrence A. May, M.D. commented, “I am pleased that we are offering these formulations through eCommerce. The initial anecdotal feedback from my patients has been consistently positive. Several of our products are being offered for the first time outside of physicians’ offices, and online sales will allow Tauriga to reach more people who could derive benefit from our supplements in supporting well-being and enhancing function.”
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a balanced portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on the Company’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which the Company has little or no control. Such forward-looking statements are made only as of the date of this release, and the Company assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by the Company with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
Food and Drug Administration Disclaimer: None of the statements contained in this press release regarding any of the products either offered or to be offered in the future by the Company have been evaluated by the Food and Drug Administration. Additionally, none of the products is intended to diagnose, treat, cure, or prevent any disease.
Tauriga Sciences, Inc.:
Dr. Stella M. Sung,
Chairman and Chief Executive Officer
Tauriga Sciences, Inc.
San Diego: + 1-858-353-5749
Montreal: + 1-514-840-3697